Jeantine Lunshof
Jeantine Lunshof is a philosopher and bioethicist. Since 1992, she has been involved in international research collaborations on ethical issues in human genetics. She holds affiliations with the Department of Molecular Cell Physiology, VU University, Amsterdam, The Netherlands, The Netherlands Institute for Systems Biology (NISB), and with (CESAGen), Cardiff University, UK. Her current work focuses on the ethical and public-policy aspects of pharmacogenomics, genome-wide association studies and personalized medicine, and on the philosophy of systems biology. Jeantine has been an ethics consultant to the Personal Genome Project at Harvard Medical School, Genetics Department, since early 2006. She is an affiliate member of the NIH Pharmacogenetics Research Network (PGRN), and a Member of the Public Population Project in Genomics (P3G) Consortium.
Biography Updated on 29 May 2008
Personal Home Page
http://www.bio.vu.nl/microb/personnel/jeantine_lunshof/index.html
Articles in Scholarly Journals [Incomplete List]
- Hippocrates revisited? Old ideals and new realities
Genomic Medicine, 2008 - From genetic privacy to open consent
Nature Reviews Genetics, vol. 9, no. 5, Article ID nrg2360, 5 pages, 2008 - Personalized medicine: decades away?
Pharmacogenomics, vol. 7, no. 2, pp. 237–241, 2006 - Teaching and practicing pharmacogenomics: a complex matter
Pharmacogenomics, vol. 7, no. 2, pp. 243–246, 2006 - Personalized medicine: new perspectives - new ethics?
Personalized Medicine, vol. 3, no. 2, pp. 187–194, 2006 - Desperate times call for desperate measures
Nature Reviews Genetics, vol. 7, no. 3, pp. 162–162, 2006 - Molecular medicine: a lifetime of learning, teaching and caring
Trends in Molecular Medicine, vol. 11, no. 11, pp. 484–485, 2005 - A call for the creation of personalized medicine databases
Nature Reviews Drug Discovery, vol. 5, no. 1, pp. 23–26, 2005 - Personalized medicine: how much can we afford? A bioethics perspective
Personalized Medicine, vol. 2, no. 1, pp. 43–47, 2005 - Pharmacogenomics, drug development, and ethics: Some points to consider
Drug Development Research, vol. 62, no. 2, pp. 112–116, 2004